SUMMARY
Almost two decades have passed since opioids were first injected epidurally and intrathecally to produce spinal analgesia in humans. In this time, a large number of different drugs have been used and there remains controversy over their relative advantages and disadvantages. Epidural morphine provides high quality analgesia of long duration but is associated with a relatively high incidence of side-effects, including the risk of delayed depression from cephalad migration in cerebrospinal fluid (CSF). The highly lipid soluble opioids such as fentanyl undergo more rapid absorption from CSF and have less potential for cephalad transfer. However, for these drugs, there is controversy whether the epidural route of administration has significant advantages over conventional intravenous administration.
Pethidine is an opioid with intermediate lipid solubility that is effective by the epidural route. In Australia and New Zealand, epidural pethidine has enjoyed popularity amongst anaesthetists, particularly in obstetrics, although it has been less popular in other parts of the world, notably in the United States 1 . This paper reviews the pharmacology of epidural pethidine and clinical experience reported to date. Articles reviewed include those identified by a Medline search using keywords "epidural" or "extradural" and "pethidine" or "meperidine". Reference lists from identified papers were scrutinized to identify further relevant articles.
HISTORY
The analgesic properties of pethidine were discovered by Eisleb and Schaumann in 1939 when they were investigating the potential spasmolytic properties of compounds with similar structure to atropine 2 . Known as meperidine in North America, pethidine was one of the first opioids to be injected epidurally in humans. Following the initial report of the use of epidural morphine in treatment of pain 3 , Cousins et al. described epidural and intrathecal injection of pethidine for the relief of chronic and postoperative pain in patients with cancer 4 . The term "selective spinal analgesia" was coined to describe analgesia obtained without evidence of changes in sensory, sympathetic or motor function. Following this initial report, a number of papers were published attesting to the efficacy of epidural pethidine for the treatment of acute pain. Epidural pethidine gained particular popularity in obstetrics where it was investigated for both labour analgesia and analgesia during and after caesarean section. Brownridge demonstrated the efficacy of single doses of epidural pethidine 5, 6 and subsequently, continuous epidural infusion 7 and delivery by patient-controlled epidural analgesia were described 8, 9 .
PHARMACOLOGY
Pethidine (ethyl 1-methyl-4-phenylpiperidine-4-carboxylate, Figure 1 ) is a synthetic phenylpiperidine opioid agonist with lipid solubility that is intermediate between morphine and most of the other opioids in clinical use [10] [11] [12] [13] . It is a weak base with pKa 8.5, which is similar to that of other opioids (Table 1) . In Australia and New Zealand, common commercial preparations of pethidine have a concentration of 50 mg/ml and are preservative-free. A preparation that has been prediluted to a concentration of 50 mg/10 ml specifically for epidural administration is also available. Pethidine is an agonist at the mu opioid receptor and causes potent spinal and supraspinal analgesia.
Following epidural injection, pethidine undergoes rapid absorption across the dura. Concentrations of pethidine in CSF increase in parallel with the onset of analgesia, with maximum levels reached in 15 to 43 minutes 14, 15 . A similar fraction of a bolus of epidural pethidine (3.7%) crosses the dura compared with epidural morphine, but the rate of transfer across the dura is significantly faster with pethidine 14 . Following epidural pethidine 30 mg, CSF concentrations were higher than concurrently measured plasma concentrations and the CSF concentration at the time of request for further analgesia was 1100 ng/ml 14 .
Pethidine is removed at a faster rate from CSF than is morphine after lumbar epidural injection 14 . This reduces the potential for cephalad migration and supraspinal adverse effects and explains why, unlike morphine, delayed respiratory depression is rare after epidural pethidine. However, concentrations of 1400 to 1650 ng/ml were found in CSF samples taken at the C7-T1 vertebral level 10 to 60 min after lumbar epidural injection of pethidine 50 mg, showing that some cephalad migration does occur 16 . Vascular uptake occurs rapidly after epidural injection of pethidine. Peak concentrations occur within 10-15 min and the reported terminal elimination half life has ranged from 124 to 324 min 14, 15, 17 . Sjöström et al reported peak plasma concentrations of pethidine of 196 ng/ml after a dose of 30 mg which is below the reported minimum effective analgesic concentration (MEAC) of pethidine in plasma of 460 ng/ml 18 . In comparison, after a dose of 100 mg, Husemeyer et al reported that peak plasma concentrations of pethidine were greater than 600 ng/ml and Nordberg et al reported that mean peak plasma concentration of pethidine was 1210 ng/ml. Ngan Kee et al administered epidural pethidine in doses ranging from 12.5 mg to 100 mg and found that peak plasma concentrations of pethidine were below MEAC for doses of 12.5 to 75 mg but were greater than MEAC after 100 mg 19 . These data suggest that although analgesia from smaller doses of epidural pethidine appears to be mediated predominantly at a spinal cord level, systemic effects are likely when higher doses are used. When repeated doses of epidural pethidine were given over 24 h using patient-controlled epidural analgesia, dose requirement was less and analgesia was better compared with intravenous pethidine, which is further evidence for a spinally-mediated site of action 20 . Pethidine is metabolized in the liver where it is extensively degraded by N-demethylation to norpethidine and by hydrolysis to pethidinic acid. The elimination half-life of pethidine is 3 to 6 h. The metabolites are excreted by the kidney in the free form and as conjugates with glucuronic acid 21 . The half-life of norpethidine is approximately 15 h, but this may be increased up to 35 h in patients with renal failure 22 . Pethidine in common with other phenylpiperidine opioids has local anaesthetic activity [23] [24] [25] . When administered at a dose of 2.6 to 3.8 mg/kg, epidural pethidine was reported to provide surgical anaesthesia in five critically ill patients undergoing gynaecological and orthopaedic surgery 26 determined whether the local anaesthetic properties of pethidine contribute to analgesia in this setting. A study of CSF concentrations of pethidine after intrathecal injection suggested that very high concentrations of pethidine are required for motor and sensory block 14 and investigation of the haemodynamic effects of epidural pethidine in parturients using thoracic bioimpedence cardiography did not demonstrate significant changes changes after injection of 10 ml pethidine 0.5% 27 .
CLINICAL EXPERIENCE

Acute Postoperative Pain
The major application for epidural pethidine has been in the treatment of acute postoperative pain. In initial reports, a dose of 100 mg given via a catheter sited in a thoracic vertebral interspace gave rapid onset of analgesia with duration 4 to 20 h in patients having surgery for cancer 4, 28 . Subsequently, epidural pethidine has been shown to provide effective analgesia, alone and in combination with other drugs, after a variety of surgical procedures. A number of studies have compared epidural administration of pethidine with conventional intramuscular and intravenous administration and have shown better analgesia with lower drug requirement with the epidural route 20, [29] [30] [31] . In contrast, it has been suggested that for highly lipid soluble opioids such as fentanyl and sufentanil, analgesic efficacy and dose requirements may be similar between epidural and conventional administration 32, 33 .
Single Bolus Injection
Single bolus injections of epidural pethidine were shown by Brownridge to be an effective and safe method for analgesia after caesarean section 5, 6 . Doses could be conveniently administered by nursing staff on general wards. The technique was particularly suited to this patient group since epidural catheters were commonly inserted as part of the anaesthetic technique and midwives had experience of managing epidural analgesia in labour wards. Initial reports described intermittent boluses of pethidine 50 mg diluted to 10 ml with saline which gave better analgesia than intramuscular pethidine 100 mg 29, 30 . A subsequent dose-response study in Asian patients showed that a smaller dose of 25 mg provided similar analgesia to doses of 50 mg and greater, but with lower resultant plasma concentrations of pethidine 19 . A wide variation of duration of analgesia has been reported after single boluses of epidural pethidine after caesarean section and other types of surgery.
The reported duration of analgesia from doses ranging from 25 to 100 mg has varied from 1.5 to 20h 19, 28, [34] [35] [36] [37] [38] [39] . Some of this variation can be explained by differences in the types of patient and surgery and differences in method of assessing the duration of analgesia. In a direct comparison of doses ranging from 12.5 to 100 mg after caesarean section, duration of analgesia was greater after 25 mg (median 165 min) compared with 12.5 mg (83 min), but increasing the dose to 50 to 100 mg did not increase the duration further 19 . No correlation was found between duration of analgesia and patients' weight or height. In that study, further analgesia was freely available by patient-controlled epidural analgesia (PCEA) and duration of analgesia, defined by time to first PCEA demand, was accurately recorded by the electronic memory of the PCEA device.
Single boluses of pethidine, in common with other epidural opioids, are usually diluted before epidural injection. Commonly, a diluent volume of 10 ml is chosen, probably because this is similar to the volumes in which local anaesthetics have been injected in order to obtain sufficient spread in the epidural space 13 . Increasing diluent volume enhances analgesia by facilitating adequate exposure of the spinal segments required for analgesia. However, injection of epidural opioids in large volumes may increase cephalad spread in CSF with the risk of respiratory depression 40 . Therefore, the optimum volume should be defined by the smallest volume, or greatest concentration, that can be used without loss of analgesic efficacy 38 . A study of the effect of diluent volume from epidural pethidine after caesarean section found that analgesia was better when pethidine 25 mg was injected in a volume of 5 ml compared with 2 ml, but there was no advantage in increasing the volume to 10 ml 38 . Volume had no effect on systemic absorption of pethidine. Therefore, it was concluded that 5 ml is the preferred volume for single boluses of epidural pethidine.
Recently, the addition of adrenaline 50 µg to epidural pethidine 25 mg was shown to increase the duration of analgesia and reduce systemic absorption of pethidine 39 . However, addition of adrenaline 5 µg/ml to pethidine 5 mg/ml for PCEA did not improve analgesia or reduce side-effects although it resulted in a small reduction in pethidine consumption 41 .
Continuous Epidural Infusion
Epidural pethidine 2 mg/ml infused continuously at rates of 14 to 20 mg/h and 0.33 mg/h was effective for analgesia after laparotomy and thoracotomy respec-tively 7, 42 . In the latter study, continuous epidural infusion of pethidine was compared with intravenous pethidine infusion supplemented with patientcontrolled analgesia (PCA) after thoracotomy. Patients who received epidural infusion had better analgesia with lower drug consumption and improved postoperative pulmonary function compared with patients who received intravenous pethidine. Pethidine has also been given by continuous epidural infusion in combination with local anaesthetic. Pethidine 1.5 mg/ml plus bupivacaine 0.06% infused at rates up to 20 ml/h provided good analgesia after aortic surgery that was comparable to that achieved with fentanyl 4 µg/ml plus bupivacaine 0.06% 43 .
Patient-Controlled Epidural Analgesia
Patient-controlled epidural analgesia (PCEA) combines the efficacy of epidural analgesia with the convenience and patient satisfaction derived from patient-controlled analgesia 8, 44 . A number of reports have demonstrated the effectiveness of pethidine delivery by PCEA (Table 2 ). Sjöström et al reported that analgesia by PCEA using pethidine after abdominal surgery was satisfactory and qualitatively similar to that achieved with PCEA using morphine 8 . Subsequently, Yarnell et al compared PCEA using pethidine with conventional intramuscular pethidine and found PCEA gave better analgesia with lower consumption of pethidine and was preferred by both patients and nursing staff 9 . Similarly, Paech et al showed that PCEA using pethidine was superior to patient-controlled intravenous analgesia (PCIA) using the same settings 20 . Reports of PCEA using pethidine have varied in their use of background infusions. A comparison of PCEA with and without a background infusion found that addition of an infusion increased drug consumption without improving analgesia and was not recommended 45 . Most reports of PCEA have used electronic devices. However, there have also been reports showing the feasibility of using disposable mechanical devices for delivering pethidine by PCEA 44, 46 . These have the potential advantages of simplicity, low weight and low capital cost. However, these devices have limited flexibility in program selection and have no record of patient demands. In addition, their disposable design may make accidental breakage more likely 46 . PCEA has been used to compare epidural pethidine with other opioids and drug combinations. Etches et al showed that addition of bupivacaine 1 mg/ml or 0.1 mg/ml to pethidine 1 mg/ml given by PCEA did not affect analgesia or pethidine consumption after thoracotomy 47 . Rosaeg and Lindsay compared PCEA using pethidine with single dose epidural morphine 3 mg after caesarean section and found pethidine caused less nausea and pruritus 48 . Visual analog scale pain scores were higher in the pethidine group but the concentration of pethidine they used was relatively high (10 mg/ml) and has subsequently been shown to be less effective than a concentration of 5 mg/ml 38 . Pethidine has been compared with fentanyl for PCEA after caesarean section. Goh et al randomized patients to receive PCEA using pethidine or fentanyl after caesarean section with a crossover to the other drug after 24 h and found patients had fewer sideeffects with pethidine and preferred pethidine to fentanyl 49 . In another crossover study, Ngan Kee et al randomized patients to receive pethidine or fentanyl by PCEA or PCIA after caesarean section with a crossover of route of administration after 12 h
31 . An initial loading dose of epidural pethidine 40 mg gave rapid analgesia which was similar to that achieved with epidural fentanyl 80 µg. Although the onset of analgesia was not as rapid as that achieved with intravenous loading doses, fewer side-effects were observed in the epidural groups. Subsequently in that study, PCEA had advantages over PCIA for both pethidine and fentanyl but advantages of PCEA were not present after 24 h and patients preferred PCEA over PCIA with pethidine, but not with fentanyl. Smith et al randomized patients to receive PCEA after abdominal surgery using pethidine 2.5 mg/ml, bupivacaine 0.125% plus fentanyl 10 µg/ml, or bupivacaine 0.125% plus diamorphine 125 µg/ml 50 . They found that analgesia was similar between groups but side-effects were less in the pethidine group and recommended pethidine as the better choice of solution for PCEA.
Concurrent use of other opioids during administration of epidural pethidine is not recommended. However, coadministration of nonsteroidal antiinflammatory drugs may be useful. Thus, Pavy et al found that an infusion of ketorolac 120 mg over 24 h reduced consumption of pethidine by PCEA in the first 24 h after caesarean section 51 .
Analgesia in Labour
Reports of the use of epidural pethidine for relief of pain in labour were published at a similar time to its introduction for postoperative pain. Investigations of the use of epidural pethidine alone had mixed results. Comparison of different doses showed good analgesia in only 50% of patients who received doses from 25 to 100 mg 52 . Duration of analgesia was short, ranging from a mean of 55 min after 25 mg, to 150 min after 100 mg. Comparison of epidural pethidine 100 mg with intramuscular pethidine 100 mg showed that the epidural route gave more effective analgesia. However, high plasma concentrations of pethidine were measured in the epidural group, suggesting a significant contribution from systemic effects 17 . Investigations of the mixture of pethidine with local anaesthetics for epidural injection in labour have been more favourable. Edwards et al found that addition of pethidine 50 mg to 9 ml bupivacaine 0.25% increased the duration of analgesia from a mean of 87.5 min to 122.2 min but did not improve the speed of onset or quality of analgesia compared with bupivacaine alone 53 . Brownridge et al compared pethidine 25 mg, bupivacaine 12.5 mg, pethidine 25 mg plus bupivacaine 12.5 mg, bupivacaine 25 mg, and bupivacaine 37.5 mg, each diluted to 10 ml in saline 54 . They found that analgesia was less satisfactory in patients who received pethidine 25 mg or bupivacaine 12.5 mg, motor block was greater in patients who received bupivacaine 25 mg or bupivacaine 37.5 mg, and satisfaction was greatest in patients who received the combination of pethidine and bupivacaine. Handley et al compared pethidine 25 mg plus 12.5 mg, 18.75 mg or 25 mg bupivacaine in 10 ml saline 55 . They found no difference in pain scores after 30 min and no difference in duration of analgesia between groups although onset of analgesia was more rapid in the group that received bupivacaine 25 mg. These studies suggest that the best combination of pethidine and bupivacaine for bolus doses in labour is pethidine 25 mg with bupivacaine 12.5 mg. The efficacy of pethidine added to bupivacaine for continuous epidural infusion in labour has not been established. Potential adverse effects of the use of epidural pethidine in labour are discussed below.
Intraoperative Use
There has been one report of the use of epidural pethidine for surgical anaesthesia. Kaza et al used epidural pethidine for anaesthesia for gynaecological and orthopaedic surgery in five critically ill patients 26 . However, relatively large doses of pethidine of 2.6 to 3.8 mg/kg were required and supplementation with epidural bupivacaine was required for the two patients having abdominal hysterectromy. Hsieh et al compared 8 to 16 ml of epidural pethidine 0.5% with an equal volume of bupivacaine 0.5% for extracorporeal shock wave lithotripsy 56 . Both drugs were effective. Pethidine was associated with better haemodynamic stability but a higher incidence of dizziness and sedation.
Epidural pethidine has been used to provide anal-gesia during surgery under regional anaesthesia. Paech compared epidural pethidine 50 mg with epidural fentanyl 100 µg for analgesia during caesarean section under epidural analgesia 57 . He found that analgesia was of similar quality and duration between groups but the onset was slightly faster with fentanyl. Sutherland et al compared epidural pethidine 25 mg with placebo during caesarean section under epidural analgesia and found a reduction in the incidence of shivering from 36% in the control group to 11% in the pethidine group 58 . There were no differences in maternal side-effects or neonatal Apgar scores and minimal concentrations of pethidine were detected in umbilical cord blood.
Chronic Pain
Although the initial report of clinical use of epidural pethidine demonstrated its efficacy in treating intractable pain in cancer patients 4 , epidural pethidine has not subsequently been established as a suitable drug for chronic pain management. Because longterm use of pethidine may be associated with toxicity from accumulation of norpethidine, epidural pethidine is not recommended for chronic pain conditions.
Adverse Effects
The adverse effects of epidural opioids have been reviewed previously 59, 60 . Reports in the literature have confirmed a low incidence of adverse effects with epidural pethidine. Brownridge reported large series of patients who received epidural pethidine after caesarean section administered by nurses on general wards without serious complications 5, 6 . There have been occasional reports of early respiratory depression occurring shortly after relatively large doses of epidural pethidine. Rosaeg et al reported a patient in whom the respiratory rate decreased to 4/min and arterial haemoglobin oxygen saturation decreased to 90% thirty minutes after epidural meperidine 75 mg was given during caesarean section under epidural anaesthesia 61 . The patient improved after intravenous naloxone was given and there were no sequelae. The authors considered that this was the result of systemic absorption of pethidine and recommended that the doses of pethidine for postpartum analgesia be limited to 50 mg. Similarly, Yarnell et al also reported a patient who became sedated and bradypnoeic and required naloxone after epidural pethidine 75 mg was given intraoperatively during caesarean section 9 . Paech reported a patient in whom the respiratory rate decreased from 16/min to 8/min five minutes after injection of epidural pethidine 50 mg 57 . No treatment was given. Brownridge et al reported early respiratory depression that occurred shortly after injection of pethidine 50 mg through an epidural catheter that was subsequently shown to be placed in the subarachnoid space 62 . A single case of delayed respiratory depression after epidural pethidine was reported by Albright who monitored respiration using a respiratory apnoea monitor after epidural injection of morphine, hydromorphone or pethidine after caesarean section 63 . This patient had a respiratory rate of eight per minute when sleeping, five hours after epidural pethidine 75 mg. However, respiratory rate was 18/min on arousal, there was no note of naloxone being required, and there was no respiratory depression after two subsequent doses of epidural pethidine. Thus it is questionable whether this case represented clinically significant respiratory depression and a review of respiratory depression associated with spinal opioids concluded that delayed respiratory depression is a rare event following a single dose of epidural pethidine 59 . Studies that have compared epidural pethidine with intramuscular and intravenous pethidine have shown equal or lower incidences of side-effects such as nausea, pruritus, dizziness and sedation with epidural pethidine compared to the conventional routes. Paech et al found that patients receiving pethidine by PCEA were less sedated than patients receiving PCIA 20 . Comparative studies have shown epidural pethidine to have fewer side-effects compared with morphine 48 and fentanyl 49 and mixtures of fentanyl with bupivacaine and diamorphine with bupivacaine 50 . In general, reports of the use of epidural pethidine have not shown a high incidence of pruritus 20, 48, 49 but there have been no adequate studies to determine whether the incidence is less than with other opioids.
A single case has been reported of hypertension after epidural pethidine. Robinson and Metcalf described a 76-year-old man who developed hypertension and tachycardia during injection of pethidine through an epidural catheter for analgesia for rib fractures and postulated that this was the result of an effect of pethidine on the cardiovascular control centre 64 . However, the authors had noted bloodtinged fluid in the epidural catheter which had prompted them to withdraw the epidural catheter by one centimetre. They had not subsequently given a test dose and thus had not excluded inadvertent intravenous injection.
Few studies have compared the incidence of urinary retention with epidural pethidine with that of other epidural opioids. This may be related to the practice of many units to maintain an indwelling urinary catheter for the first 24h after caesarean section. Goh et al studied patients who were given pethidine and fentanyl by PCEA in the first 48h after caesarean section and found a similar low incidence of the need to recatheterize in both groups 49 . Data from animals suggests that epidural pethidine may have less propensity to cause urinary retention compared with epidural morphine 65 . Recrudescence of herpes simplex labialis has been described in patients receiving epidural morphine but does not appear to be associated with the use of epidural pethidine 48 although it has been reported after intrathecal pethidine 66 . Occasional complications have been reported during epidural pethidine therapy not directly associated with the drug itself. Ngan Kee et al reported an epidural abscess that occurred in a patient receiving epidural pethidine by intermittent bolus injection 67 . Hilgenhurst et al reported a patient who became paraplegic following inadvertent subdural infusion of pethidine 68 . Potential adverse effects of the use of epidural pethidine in labour include delayed maternal gastric emptying and effects on neonatal respiration and behaviour. Using paracetamol absorption, intramuscular pethidine was shown to cause a delay in gastric emptying in labouring women that was not reversible by metoclopramide 69 . This potentially may increase the risk of regurgitation and pulmonary aspiration and it has been recommended that histamine H 2 -antagonists be given to women who receive pethidine 70 . Additionally, intramuscular pethidine can cause depression of neonatal respiration and aspects of neonatal behaviour 71 . Although there are few data examining the potential for these effects after epidural administration of pethidine, the drug is detectable in both maternal and umbilical cord blood after epidural injection 72 and theoretically the same cautions should apply.
Other areas of potential concern with the use of epidural pethidine include systemic accumulation of the metabolite norpethidine and effects of secretion into breast milk. Norpethidine toxicity has been reported in patients receiving pethidine by intravenous PCA 73 and in a patient with acute renal failure 74 , but it has not been reported in patients receiving epidural pethidine. Because dose requirement is lower for epidural compared with intravenous administration of pethidine, accumulation of norpethidine should be less likely. However, epidural pethidine may be relatively contraindicated in the presence of renal function or for prolonged use. Norpethidine is excreted into the breast milk of nursing mothers. Wittels reported that infants of mothers receiving pethidine by intravenous PCA after caesarean section had lower behavioural scores compared with infants of mothers receiving morphine 75. Despite this, parenteral pethidine remains a common analgesic after caesarean section. Furthermore, because dose requirements are reduced when the epidural route is used, this should reduce the potential for norpethidine accumulation in breast milk although this is yet to be formally studied.
CONCLUSIONS
Epidural pethidine has a long history of use in the treatment of acute pain. For postoperative pain, administration of epidural pethidine by intermittent boluses, continuous infusion and patient-controlled epidural analgesia are effective. After caesarean section, a single dose of 25 mg is optimal and this should be diluted to a volume of 5 ml. The addition of adrenaline 50 µg usefully increases the duration of action. For PCEA, a bolus size of 5 to 25 mg, with lockout period of 6 to 20 min and no background infusion is effective. Epidural pethidine can be used to provide intraoperative analgesia during surgery under regional anaesthesia and may reduce the incidence of shivering. The combination of pethidine 25 mg and bupivacaine 12.5 mg is recommended for providing analgesia by intermittent epidural injection in labour.
Because pethidine has intermediate lipid solubility, it may have advantages over many other opioids used for epidural analgesia. Compared with epidural morphine, pethidine has not been associated with delayed respiratory depression and causes less nausea and pruritus. Pethidine was preferred to fentanyl in studies that used patient-controlled epidural analgesia. Epidural pethidine has consistently been shown to provide better analgesia with lower dose requirements compared with standard parenteral administration of pethidine. This contrasts with the more lipid-soluble opioids for which there continues considerable controversy as to whether the epidural route has advantages over conventional routes. Although the commonest application of epidural pethidine has been in the area of obstetric anaesthesia, available data suggests that epidural pethidine is also effective in other patient groups. Future investigation may more clearly delineate the role of epidural pethidine in these areas.
Limitations in the use of epidural pethidine include the potential for toxicity of its major metabolite, norpethidine. Epidural pethidine should be used with caution in patients with impaired renal function or in those for whom the requirement for analgesia is anticipated to be prolonged. Although neonatal toxicity from transmission of pethidine and norpethidine into breast milk has not been reported as a clinical problem, the risk is yet to be scientifically quantified. Epidural pethidine is absorbed into the systemic absorption and early respiratory depression has been reported. Therefore, close postoperative observation of patients, including regular monitoring of level of consciousness and respiratory function, is mandatory and concurrent administration of other opioids should be avoided.
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